GAF Healthcare
Обзор направления

Лучшие больницы для «Irritable Bowel Syndrome Treatment» в ОАЭ

3 больниц по направлению «Хирургическая гастроэнтерология» представлены в нашей сети в ОАЭ, с аккредитацией Hospital Certificates of Services, JCI.

3
больниц в списке
1
город
4.5
средний рейтинг
2
вида аккредитации
Короткий ответ

На этой странице перечислены больницы направления «Хирургическая гастроэнтерология» (включая Irritable Bowel Syndrome Treatment) в ОАЭ, включая Burjeel Hospital for Advanced Surgery Dubai, Kings College Hospital Dubai, Aster Hospital Dubai.

Спросите нас о «Irritable Bowel Syndrome Treatment» в ОАЭ

Оставьте свои данные — наша команда координации свяжется с вами и расскажет о следующих шагах.

Сравните 3 аккредитованных больниц (Хирургическая гастроэнтерология) в ОАЭ

🇦🇪 Burjeel Hospital for Advanced Surgery Dubai

Dubai, UAE 4.5 (1 отзывов) 209 коек
Почему стоит выбрать эту больницу?
Рейтинг 4.5 из 5 (1 отзывов)Аккредитация: Hospital Certificates of Services209 коек
Специализации и аккредитация
OrthopedicsCardiac SciencesCosmetic SurgeryGastroenterologyGeneral SurgeryGynecology
Аккредитация Hospital Certificates of Services
Полный профиль →
4.5/5
Рейтинг
2014
Основана в
209
Койки
Dubai, UAE
Расположение
Kings College Hospital Dubai

🇦🇪 Kings College Hospital Dubai

Dubai, UAE 4.5 (1 отзывов) 100 коек
Почему стоит выбрать эту больницу?
Рейтинг 4.5 из 5 (1 отзывов)Аккредитация: Hospital Certificates of Services100 коек
Специализации и аккредитация
Cardiac SciencesCosmetic SurgeryENTGastroenterologyGeneral SurgeryGynecology
Аккредитация Hospital Certificates of Services
Полный профиль →
4.5/5
Рейтинг
2014
Основана в
100
Койки
Dubai, UAE
Расположение
Aster Hospital Dubai

🇦🇪 Aster Hospital Dubai

Dubai, UAE 4.5 (1 отзывов) 114 коек
Почему стоит выбрать эту больницу?
Рейтинг 4.5 из 5 (1 отзывов)Аккредитация: JCI114 коек
Специализации и аккредитация
BariatricCardiac SciencesCosmetic SurgeryENTGastroenterologyGeneral Surgery
Аккредитация JCI
Полный профиль →
4.5/5
Рейтинг
1987
Основана в
114
Койки
Dubai, UAE
Расположение
Наша методология

Как мы выбираем эти больницы

Больница появляется на этой странице, если направление «Хирургическая гастроэнтерология» указано среди её специализаций и она находится в ОАЭ. Сортировка — по указанному рейтингу (по убыванию), без редакционного рейтинга «лучших».

На что обратить внимание

Как выбрать лучшую больницу для «irritable bowel syndrome treatment» в ОАЭ?

Выбор подходящей больницы для «irritable bowel syndrome treatment» — важное решение в вашем пути лечения. Вот на что стоит обратить внимание:

Международная аккредитация

Ищите больницу с международной аккредитацией, например JCI или NABH — см. отметки аккредитации у каждой больницы ниже.

Специализация

Убедитесь, что в больнице есть отделение, специализирующееся на «Хирургическая гастроэнтерология», а не только общая помощь.

Мощность и опыт

Количество коек и год основания, указанные ниже, отражают масштаб и операционный опыт больницы.

Прозрачность стоимости

Запросите детализированную смету перед поездкой — используйте наш калькулятор стоимости для первичной оценки.

Клинический обзор

Что нужно знать о процедуре «Irritable Bowel Syndrome Treatment»

Irritable Bowel Syndrome (IBS) is a chronic functional gastrointestinal disorder affecting up to 15% of the global population, characterized by recurrent abdominal pain, altered bowel habits, and significant impairment of quality of life. With a comprehensive symptom management success rate of 70–85% using multimodal treatment protocols, IBS can be effectively controlled through a combination of dietary intervention, gut-directed pharmacotherapy, and psychological therapies. GAF Healthcare connects international patients with top-tier gastroenterology centers in India and the UAE, offering evidence-based, individualized IBS management at a fraction of Western costs, backed by JCI and NABH/DHA-accredited institutions.

0–2 days (most consultations and treatments are outpatient; hospitalization only for severe refractory cases or diagnostic procedures such as colonoscopy)
Hospital Stay
1–3 weeks (sufficient for initial specialist evaluation, diagnostic workup, therapeutic protocol initiation, and dietary/behavioral counseling completion)
Total Stay in Country (Fit-to-Fly)
70–85% significant symptom improvement with multimodal therapy
Success Rate

Clinical Overview

Irritable Bowel Syndrome is classified as a disorder of gut-brain interaction (DGBI), formerly termed a functional gastrointestinal disorder, per the Rome IV diagnostic criteria established in 2016. The condition manifests as recurrent abdominal pain at least one day per week over the preceding three months, associated with two or more of the following: relation to defecation, change in stool frequency, or change in stool form. IBS is further subtyped into IBS-C (constipation-predominant), IBS-D (diarrhea-predominant), IBS-M (mixed bowel habits), and IBS-U (unclassified), each requiring a distinct therapeutic approach. The pathophysiology is multifactorial, involving visceral hypersensitivity mediated by sensitized afferent nociceptors in the enteric nervous system, dysregulation of the gut-brain axis (including serotonin signaling pathways — 90–95% of the body's serotonin is produced in the gut), intestinal microbiome dysbiosis, low-grade mucosal inflammation, altered intestinal permeability, and psychosocial comorbidities such as anxiety and depression.

Подробнее →

Who is a Candidate?

  • ELIGIBLE PATIENTS:
  • Adults and adolescents (≥18 years for most pharmacological protocols; pediatric IBS managed separately) with a Rome IV–confirmed diagnosis of IBS-C, IBS-D, IBS-M, or IBS-U
  • Patients who have failed first-line dietary and lifestyle modifications for ≥3–6 months without adequate symptom relief
  • Patients with refractory IBS seeking second or third-line pharmacological or psychological interventions not accessible or affordable in their home country
  • Patients requiring diagnostic exclusion of organic disease (IBD, colorectal cancer, celiac disease, microscopic colitis) prior to IBS management
  • +20 more

Treatment Options & Approaches

IBS management is non-surgical and follows an evidence-based stepwise multimodal approach. Treatment is individualized based on IBS subtype (IBS-C, IBS-D, IBS-M), symptom severity (mild/moderate/severe per IBS-SSS), and the presence of comorbid psychological conditions.

STEP 1: Dietary & Lifestyle Interventions (first-line)

  • Low-FODMAP Diet (Fermentable Oligosaccharides, Disaccharides, Monosaccharides, and Polyols): The most robustly evidence-based dietary intervention for IBS, with 50–86% of patients experiencing significant symptom reduction. Conducted in three structured phases: Elimination (2–6 weeks), Reintroduction (systematic FODMAP category re-challenge), and Personalization. Requires supervision by a trained dietitian with IBS expertise. Available in structured outpatient programs at GAF Healthcare partner centers.
  • Soluble Fiber Supplementation: Psyllium husk (ispaghula) is recommended for IBS-C and IBS-M (evidence level: strong). Insoluble fiber (wheat bran) may worsen symptoms and is generally avoided.
  • Gut-Healthy Lifestyle Counseling: Regular physical activity (150 min/week moderate intensity), sleep hygiene, and stress reduction strategies — all evidence-based adjuncts.
  • Probiotics: Specific strains with evidence include Bifidobacterium infantis 35624, Lactobacillus plantarum 299v, and multi-strain preparations. Used as adjunct therapy; response is strain-specific and patient-variable.

STEP 2: Gut-directed Pharmacotherapy (second-line)

Подробнее →

Восстановление

PHASE 1 — PRE-TRAVEL PREPARATION (2–4 weeks before departure):

  • Step 1: Submit medical records to GAF Healthcare coordinator via secure portal (previous colonoscopy/endoscopy reports, blood work, imaging, current medications, and completed Rome IV symptom questionnaire and IBS-SSS)
  • Step 2: GAF Healthcare medical team conducts virtual pre-consultation with the assigned gastroenterologist (India or UAE) to review records, confirm diagnosis, identify diagnostic gaps, and outline a personalized treatment plan
  • Step 3: GAF Healthcare arranges e-Medical Visa (India) or UAE entry visa documentation, airport transfer scheduling, and hospital appointment coordination
  • Step 4: Patient begins Low-FODMAP elimination phase under dietitian guidance (can be initiated remotely via GAF-partnered telehealth dietitian)

PHASE 2 — ARRIVAL & DIAGNOSTIC WORKUP (Days 1–4):

Подробнее →

Возможные риски

IBS itself carries no mortality risk and is not a pre-malignant condition; however, patients and clinicians must remain vigilant regarding several important considerations. The primary clinical risk is diagnostic error — IBS is a diagnosis of exclusion, and alarm features (unintentional weight loss >10% body weight, rectal bleeding, nocturnal symptoms, iron-deficiency anemia, age of onset >50 years, family history of colorectal cancer or IBD, elevated fecal calprotectin >200 µg/g) mandate thorough organic disease exclusion before IBS-directed therapy is initiated. Failure to identify coexisting celiac disease (present in 4–5% of IBS-D patients) or microscopic colitis (particularly in older women on NSAIDs or PPIs) represents a significant diagnostic pitfall. Pharmacological risks are agent-specific: alosetron carries a rare but serious risk of ischemic colitis and severe constipation (approximately 1 in 1,000 patients), requiring REMS program enrollment; eluxadoline is contraindicated in patients without a gallbladder due to risk of sphincter of Oddi spasm and pancreatitis; rifaximin is generally well-tolerated but should be used judiciously to minimize microbiome disruption and rare Clostridioides difficile overgrowth. Long-term use of stimulant laxatives (bisacodyl, senna) may lead to colonic hyposensitivity; osmotic agents (PEG) have a superior long-term safety profile. Psychological comorbidities — anxiety, depression, and somatic symptom disorder — are present in a high proportion of IBS patients and, if unaddressed, significantly predict poor treatment response; psychological screening and referral are therefore integral to a responsible IBS management program. Patients should be counseled that IBS is a chronic relapsing-remitting condition: treatment goals are symptom control, functional improvement, and quality-of-life enhancement rather than cure, and ongoing self-management strategies (dietary adherence, stress regulation, sleep hygiene) remain critical long-term.

Почему GAF Healthcare

GAF Healthcare provides comprehensive end-to-end logistical support for international patients seeking IBS treatment in India and the UAE, ensuring that the non-medical aspects of the journey are seamlessly managed.

Частые вопросы о процедуре «Irritable Bowel Syndrome Treatment»

What is the cost of IBS treatment in India vs. UAE?
The cost of a comprehensive IBS management program — including specialist gastroenterology consultations, diagnostic workup (fecal calprotectin, hydrogen-methane breath test for SIBO, colonoscopy with biopsies where indicated, celiac serology, thyroid function), pharmacotherapy prescription, Low-FODMAP dietitian sessions, and gut-directed psychotherapy (where included) — ranges from approximately $500 to $2,500 USD in India, and from $1,200 to $5,000 USD in the UAE (Dubai/Abu Dhabi). India is typically 50–65% less expensive than the UAE for equivalent clinical care. The lower end of the cost range reflects straightforward outpatient consultation and pharmacotherapy initiation without colonoscopy. The higher end reflects a comprehensive diagnostic package including colonoscopy, anorectal manometry, SIBO breath testing, structured Low-FODMAP program, and a course of gut-directed CBT or hypnotherapy sessions. Both destinations offer internationally accredited facilities: NABH and JCI-accredited hospitals in India, and JCI and Dubai Health Authority (DHA)-licensed centers in the UAE. GAF Healthcare provides transparent, itemized cost estimates prior to travel with no hidden charges.
How long do I need to stay in India or the UAE before I am fit to fly home after IBS treatment?
For the majority of international patients, a stay of 1 to 3 weeks is recommended to complete the full initial IBS management program. Since IBS treatment is primarily outpatient and non-surgical, there are no surgical wounds, mobility restrictions, or post-anesthesia recovery periods that affect fitness to fly. However, an adequate in-country stay is clinically valuable to allow completion of the diagnostic workup (colonoscopy requires same-day recovery of 1–2 hours; hydrogen-methane breath test is a 3-hour fasting procedure), initiation and tolerability assessment of pharmacotherapy (physicians prefer to observe patients for 5–7 days on new medications such as rifaximin, linaclotide, or amitriptyline to ensure there are no adverse reactions), and completion of at least 2–3 initial sessions of gut-directed CBT or hypnotherapy where enrolled. Patients are typically declared fit to fly within 10–14 days of arrival. All subsequent follow-up, Low-FODMAP reintroduction phases, and psychotherapy sessions can be continued remotely via GAF Healthcare's telemedicine platform after the patient returns home.
What is the success rate of IBS treatment at GAF Healthcare partner centers?
The success rate of multimodal IBS treatment at GAF Healthcare's accredited gastroenterology partner centers is 70–85% for significant and clinically meaningful symptom improvement, defined as a reduction of ≥50 points on the validated IBS-Symptom Severity Score (IBS-SSS). Specific treatment modality success rates are as follows: the Low-FODMAP diet achieves symptom response in 50–86% of adherent patients; rifaximin (for IBS-D/SIBO) produces global symptom relief in 40–50% of patients per treatment course, with similar efficacy on repeat courses; linaclotide (for IBS-C) achieves abdominal pain reduction and improved bowel frequency in approximately 50–60% of patients vs. placebo; gut-directed hypnotherapy achieves response rates of 70–80% in refractory IBS with sustained effects at 5-year follow-up; anorectal biofeedback for concurrent dyssynergic defecation achieves remission in 70–80% of patients. It is important to note that IBS is a chronic, relapsing-remitting condition, and 'success' is defined as sustained symptom control and improved quality of life rather than complete cure. Long-term outcomes depend significantly on sustained dietary adherence, ongoing stress management, and maintenance pharmacotherapy where appropriate — all of which are supported through GAF Healthcare's structured remote follow-up program.

Как GAF Healthcare помогает выбрать лучшую больницу для «irritable bowel syndrome treatment» в ОАЭ

Найдите лучшие больницы для «irritable bowel syndrome treatment» в ОАЭ

На этой странице представлено 3 больниц в ОАЭ, чтобы вы могли сравнить аккредитацию и специализации в одном месте.

Поддержка, когда она нужна

Отправьте нам свои медицинские отчёты в WhatsApp или по email — наша медицинская команда изучит их и предложит больницу и план лечения.

Прозрачные, всё включено цены

Мы предоставляем единую детализированную смету, покрывающую расходы больницы и проживание — без скрытых платежей.

Организация визы, поездки и проживания

После выбора больницы мы помогаем оформить визовое приглашение, забронировать проживание рядом с больницей и организовать трансфер.

Хотите узнать примерную стоимость лечения? Используйте наш калькулятор стоимости для персональной оценки.

Частые вопросы

Частые вопросы о «Irritable Bowel Syndrome Treatment» в ОАЭ

Сколько больниц направления «Хирургическая гастроэнтерология» представлено в ОАЭ?
Сейчас в ОАЭ представлено 3 больниц.
Как вы выбираете больницы для списка?
Больница появляется на этой странице, если направление «Хирургическая гастроэнтерология» указано среди её специализаций и она находится в ОАЭ. Сортировка — по указанному рейтингу (по убыванию), без редакционного рейтинга «лучших».
Сколько стоит лечение в ОАЭ?
Стоимость зависит от больницы, города и конкретного случая. Используйте наш калькулятор стоимости для персональной оценки.
🤔

Остались вопросы?

Наша команда готова ответить на вопросы о «Irritable Bowel Syndrome Treatment» в ОАЭ.

Следующий шаг

Отправьте нам свои медицинские отчёты — наша команда предложит больницу и план лечения для «Irritable Bowel Syndrome Treatment» в ОАЭ.

Свяжитесь с нами, если заметите неточность на этой странице.